Contact
Please use this form to send email to PR contact of this press release:
Entasis Therapeutics Receives Positive Feedback from FDA End-of-Phase 2 Meeting for ETX2514SUL; Signs Rapid Diagnostic Agreement with bioMérieux
TO: